HCPCS Level II code Q5140 identifies an injectable biosimilar, adalimumab-fkjp, billed per 1 mg. As a biosimilar to adalimumab, this drug is used across multiple immune-mediated inflammatory conditions and is billed separately from the administration service. Nationally, biosimilar biologics like adalimumab-fkjp matter for cost management, formulary strategies, and clinical substitution policies given their potential to lower biologic therapy expenditure while maintaining therapeutic options.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role and billing context, plus what to look for in payer coverage policies: how payers position biosimilars on formularies, typical site-of-service implications (outpatient clinic/physician office), and common considerations for billing the drug product separately from the injection or infusion service. The report also outlines where to find policy updates and benchmarks when available.

This summary is written for a national audience and focuses on the code’s clinical description, payer relevance, and the types of benchmarking and policy updates readers can expect to find in the full publication. Data not available in the input will be noted where applicable.